Medicus Pharma (MDCX) Stock Price, News & Analysis

Company Overview

Medicus Pharma, Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access.

Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.

Key Stats

• Today's Range: $2.15 to $2.45
• 50-Day Range: $1.83 to $3.40
• 52-Week Range: $1.79 to $8.94
• Volume: 265,157 shs
• Average Volume: 389,387 shs
• Market Capitalization: $42.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.50
• Consensus Rating: Strong Buy

Medicus Pharma Stock Analysis - MarketRank™

Medicus Pharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 796th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Medicus Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Medicus Pharma has a consensus price target of $23.50, representing about 875.1% upside from its current price of $2.41.

Amount of Analyst Coverage

Medicus Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Medicus Pharma are expected to decrease in the coming year, from ($1.14) to ($1.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicus Pharma is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicus Pharma is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicus Pharma has a P/B Ratio of 8.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.71% of the float of Medicus Pharma has been sold short.

Short Interest Ratio / Days to Cover

Medicus Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicus Pharma does not currently pay a dividend.

Dividend Growth

Medicus Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.71% of the float of Medicus Pharma has been sold short.

Short Interest Ratio / Days to Cover

Medicus Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.13

News Sentiment

Medicus Pharma has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Medicus Pharma this week, compared to 2 articles on an average week.

Search Interest

Only 14 people have searched for MDCX on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

MarketBeat Follows

17 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicus Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.20% of the stock of Medicus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

MDCX Stock Analysis - Frequently Asked Questions

How have MDCX shares performed this year?

Medicus Pharma's stock was trading at $2.43 at the beginning of the year. Since then, MDCX stock has decreased by 0.8% and is now trading at $2.41.

How were Medicus Pharma's earnings last quarter?

Medicus Pharma Ltd (NASDAQ:MDCX) announced its earnings results on Monday, August, 11th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04.

When did Medicus Pharma IPO?

Medicus Pharma (MDCX) raised $4 million in an initial public offering (IPO) on Thursday, November 14th 2024. The company issued 1,000,000 shares at a price of $4.13 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital Markets was co-manager.

Who are Medicus Pharma's major shareholders?

Top institutional investors of Medicus Pharma include Interchange Capital Partners LLC (11.69%), Guyasuta Investment Advisors Inc. (0.57%), SeaCrest Wealth Management LLC (0.34%) and May Hill Capital LLC (0.26%).
View institutional ownership trends.

How do I buy shares of Medicus Pharma?

Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MDCX
• Previous Symbol: NASDAQ:MDCX
• CIK: 1997296
• Web: www.medicuspharma.com
• Phone: 732-300-3046
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medicus Pharma: $23.50
• High Price Target: $27.00
• Low Price Target: $20.00
• Potential Upside/Downside: +875.1%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -549.30%
• Return on Assets: -228.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.29
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 8.31

Miscellaneous

• Outstanding Shares: 17,820,000
• Free Float: 15,821,000
• Market Cap: $42.95 million
• Optionable: N/A
• Beta: N/A